Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients.

Abstract

WHAT IS KNOWN AND OBJECTIVE:

Camrelizumab is a recently developed PD-1 inhibitor in China applied in treating different cancers including lung cancer. This study is designed to evaluate the efficacy, safety and prognostic factors for camrelizumab plus carboplatin and pemetrexed (CP) chemotherapy in treating patients with advanced lung adenocarcinoma.

METHODS:

Of 51 advanced lung adenocarcinoma patients with negative driver genes who received camrelizumab plus CP chemotherapy were recruited. These patients received four cycles of camrelizumab plus CP chemotherapy in a 21-day cycle. Then, camrelizumab, pemetrexed or camrelizumab plus pemetrexed was administered as maintenance therapy.

RESULTS AND DISCUSSION:

The rates of complete response, partial response, stable disease and progressive disease were 2.0%, 56.8%, 19.6% and 5.9%, respectively; while treatment response of 15.7% of patients was missing or not evaluable. The objective response and disease control rates were 58.8% and 78.4%, respectively. With a median follow-up period of 14.9 months (the follow-up duration ranged from 3.9 months to 24.3 months), 41 (83.4%) cases of disease progression and 22 (43.1%) cases of death were recorded. The median progression-free survival (PFS) was 10.5 months (95% confidence interval (CI): 8.4-12.6 months) with a 1-year PFS rate of 36.3% and a 2-year PFS rate of 7.5%. In addition, the median overall survival (OS) was 18.7 months (95% CI: 16.4-21.0 months) with a 1-year OS rate of 79.1% and a 2-year OS rate of 30.4%. In consideration of safety, the most frequent adverse events were peripheral neuropathy (37.3%), neutropenia (37.3%), alopecia (35.3%), etc. and most of them were grade 1-2 and could be controlled.

WHAT IS NEW AND CONCLUSION:

Camrelizumab plus CP chemotherapy achieves favourable efficacy and tolerable adverse events in advanced lung adenocarcinoma patients.

• Authors: Jialing Lv, Wen Zhang, Ruoyu Deng, Yanqiong Chen, Meiyan Liu, Zhijun Zhang, Qing Wang, Yongmei He, Yaling Liu, Fengting Wang, Zengbo Lv, Huahua Zhou, Chongxin Li, Tengfei Zhang, Yanyan Fu, Xingqiang Zhao, Qiuping Bao, Yi Miao, Lin Wang, Meifang Huang, Chao Zhang
• Journal: Journal of clinical pharmacy and therapeutics (J Clin Pharm Ther) Vol. 47 Issue 8 Pg. 1257-1263 (Aug 2022) ISSN: 1365-2710 [Electronic] England
• PMID: 35397125 (Publication Type: Journal Article)
• Copyright: © 2022 John Wiley & Sons Ltd.

Chemical References

• Antibodies, Monoclonal, Humanized
• Pemetrexed
• camrelizumab
• Carboplatin

Topics

• Adenocarcinoma of Lung (drug therapy)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Carboplatin (adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Humans
• Lung Neoplasms (pathology)
• Pemetrexed (adverse effects)
• Prognosis